Laurel Wealth Advisors LLC Has $823.80 Million Holdings in Abbott Laboratories $ABT

Laurel Wealth Advisors LLC grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 13,347.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,056,934 shares of the healthcare product maker’s stock after buying an additional 6,011,891 shares during the quarter. Laurel Wealth Advisors LLC owned approximately 0.35% of Abbott Laboratories worth $823,804,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ABT. RiverFront Investment Group LLC boosted its stake in shares of Abbott Laboratories by 0.8% in the second quarter. RiverFront Investment Group LLC now owns 15,901 shares of the healthcare product maker’s stock valued at $2,163,000 after buying an additional 133 shares during the period. Edmond DE Rothschild Holding S.A. raised its position in Abbott Laboratories by 31.3% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 107,798 shares of the healthcare product maker’s stock worth $14,662,000 after acquiring an additional 25,667 shares during the period. Aviso Financial Inc. grew its position in shares of Abbott Laboratories by 7.5% in the second quarter. Aviso Financial Inc. now owns 35,476 shares of the healthcare product maker’s stock valued at $4,825,000 after purchasing an additional 2,470 shares in the last quarter. Quadcap Wealth Management LLC raised its stake in Abbott Laboratories by 3.1% in the second quarter. Quadcap Wealth Management LLC now owns 8,414 shares of the healthcare product maker’s stock valued at $1,144,000 after purchasing an additional 251 shares in the last quarter. Finally, CreativeOne Wealth LLC raised its position in Abbott Laboratories by 82.4% in the 2nd quarter. CreativeOne Wealth LLC now owns 26,911 shares of the healthcare product maker’s stock worth $3,660,000 after purchasing an additional 12,155 shares during the period. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ABT shares. Wells Fargo & Company lifted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Barclays lifted their price target on shares of Abbott Laboratories from $159.00 to $162.00 and gave the company an “overweight” rating in a research report on Friday, October 17th. Daiwa Capital Markets upped their price objective on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a report on Tuesday, October 21st. The Goldman Sachs Group boosted their price target on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $147.00.

Abbott Laboratories Stock Down 0.5%

ABT opened at $127.44 on Tuesday. The firm’s 50 day simple moving average is $129.87 and its two-hundred day simple moving average is $131.14. The company has a market capitalization of $221.61 billion, a PE ratio of 15.97, a PEG ratio of 2.36 and a beta of 0.68. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The company had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same period last year, the firm earned $1.21 EPS. Abbott Laboratories’s revenue for the quarter was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th were issued a $0.59 dividend. The ex-dividend date was Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.9%. Abbott Laboratories’s payout ratio is 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.